Neurology
-
To outline changes made to a neurology residency program in response to coronavirus disease 2019 (COVID-19). ⋯ It has been necessary and feasible for our residency training program to undergo rapid structural changes to adapt to a medical crisis. The key ingredients in doing this successfully have been flexibility and teamwork. We suspect that many of the implemented changes will persist long after the COVID-19 crisis has passed and will change the approach to neurologic and medical training.
-
To provide the first clinical report that 2 calcitonin gene-related peptide (CGRP) therapies, a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody, can be used concomitantly to treat refractory migraine. ⋯ This study provides Class IV evidence that for patients with migraine using erenumab, rimegepant is effective for acute treatment.